Alleviation of Cedar Pollen Induced Allergic Symptoms by Orally Taken Superfine Beta-1,3-Glucan
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00276445 |
Recruitment Status
:
Terminated
First Posted
: January 13, 2006
Last Update Posted
: November 7, 2006
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Allergic Conjunctivitis | Drug: beta-1,3-glucan | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Enrollment : | 60 participants |
Allocation: | Randomized |
Intervention Model: | Crossover Assignment |
Masking: | Double |
Primary Purpose: | Prevention |
Official Title: | Alleviation of Cedar Pollen Induced Allergic Symptoms by Orally Taken Superfine Beta-1,3-Glucan - A Double-Blind Randomized Study |
Study Start Date : | January 2004 |
Study Completion Date : | June 2004 |

- Symptoms were assessed clinically by score on a allergic symptom rating scale.
- Total IgE and allergen specific IgE were measured.
- The binding capacity of beta-1,3-glucan to peripheral CD14+ cells were assessed.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 20 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- history of seasonal allergic conjunctivitis with or without rhinitis in spring (Japanese cedar pollen season) every year
- positive allergen specific IgE (> 30 IU/ml) or positive skin prick test result (wheal diameter > 3mm) to Japanese cedar, Orchard Grass pollen, or house dust-mite extract
Exclusion Criteria:
- Patients who had undergone immunotherapy in the previous 5 years
- a history of other immunological or medically relevant diseases

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00276445
Japan | |
Meiji University of Oriental Medicine | |
Kyoto, Japan, 629-0392 |
Principal Investigator: | Jun Yamada, M.D. Ph.D. | Meiji University of Oriental Medicine | |
Study Director: | Junji Hamuro, Ph.D. | Kyoto Prefectural University of Medicine | |
Study Chair: | Shigeru Kinoshita, M.D. Ph.D. | Kyoto Prefectural University of Medicine |
Additional Information:
Publications:
ClinicalTrials.gov Identifier: | NCT00276445 History of Changes |
Other Study ID Numbers: |
15-58-2 Japanese Minis. Edu. 17791261 |
First Posted: | January 13, 2006 Key Record Dates |
Last Update Posted: | November 7, 2006 |
Last Verified: | January 2004 |
Keywords provided by Meiji University of Oriental Medicine:
allergy Allergy conjunctivitis beta-1-3glucan Th1/Th2 |
Additional relevant MeSH terms:
Conjunctivitis Conjunctivitis, Allergic Conjunctival Diseases Eye Diseases Hypersensitivity, Immediate Hypersensitivity |
Immune System Diseases Beta-1,3-glucan Adjuvants, Immunologic Immunologic Factors Physiological Effects of Drugs |